Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Gregorc

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 19, 2004
Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trialG L Ceresoli, F Cappuzzo, V Gregorc, et al.
Clinical Pharmacology and Therapeutics|April 27, 2012
Associations between ABCC2 polymorphisms and cisplatin disposition and efficacyJ A Sprowl, V Gregorc, C Lazzari, et al.
The Journal of Cardiovascular Surgery|July 28, 2011
Combined treatment of non-small cell lung cancer with synchronous brain metastases: a single center experienceG Melloni, A Bandiera, V Gregorc, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|September 21, 2005
Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancerC Messa, G L Ceresoli, G Rizzo, et al.
British Journal of Cancer|January 8, 2004
Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC)F Cappuzzo, S Bartolini, G L Ceresoli, et al.
Journal of Surgical Oncology|June 22, 2000
Biological prognostic factors for early stage completely resected non-small cell lung cancerL Cagini, M Monacelli, G Giustozzi, et al.
British Journal of Cancer|July 2, 2009
Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumoursV Gregorc, A Santoro, E Bennicelli, et al.
Clinical Pharmacology and Therapeutics|August 24, 2007
Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinibV Gregorc, M Hidalgo, A Spreafico, et al.
Breast (Edinburgh, Scotland)|June 22, 2026
Primary results from EL1SSAR, a prospective phase IIIb study of first-line atezolizumab plus nab-paclitaxel therapy for patients with PD-L1-positive advanced triple-negative breast cancerL Gianni, S Delaloge, E Ciruelos, et al.
ESMO Open|February 5, 2026
Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLCN Girard, J Bar, P Baas, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 19, 2004
Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trialG L Ceresoli, F Cappuzzo, V Gregorc, et al.
Clinical Pharmacology and Therapeutics|April 27, 2012
Associations between ABCC2 polymorphisms and cisplatin disposition and efficacyJ A Sprowl, V Gregorc, C Lazzari, et al.
The Journal of Cardiovascular Surgery|July 28, 2011
Combined treatment of non-small cell lung cancer with synchronous brain metastases: a single center experienceG Melloni, A Bandiera, V Gregorc, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|September 21, 2005
Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancerC Messa, G L Ceresoli, G Rizzo, et al.
British Journal of Cancer|January 8, 2004
Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC)F Cappuzzo, S Bartolini, G L Ceresoli, et al.
Journal of Surgical Oncology|June 22, 2000
Biological prognostic factors for early stage completely resected non-small cell lung cancerL Cagini, M Monacelli, G Giustozzi, et al.
British Journal of Cancer|July 2, 2009
Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumoursV Gregorc, A Santoro, E Bennicelli, et al.
Clinical Pharmacology and Therapeutics|August 24, 2007
Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinibV Gregorc, M Hidalgo, A Spreafico, et al.
Breast (Edinburgh, Scotland)|June 22, 2026
Primary results from EL1SSAR, a prospective phase IIIb study of first-line atezolizumab plus nab-paclitaxel therapy for patients with PD-L1-positive advanced triple-negative breast cancerL Gianni, S Delaloge, E Ciruelos, et al.
ESMO Open|February 5, 2026
Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLCN Girard, J Bar, P Baas, et al.
Pageof 2